NVIDIA denies H100/H200 shortages
Serina Therapeutics, Inc. (NYSE American:SERA) reported that its board of directors amended the company’s bylaws on Monday to introduce new procedures for transactions involving potential conflicts of interest and to expand its forum selection clause.
According to a statement in a Securities and Exchange Commission filing, the amended bylaws establish a set of safe harbor procedures for acts or transactions in which directors, officers, controlling stockholders, or control groups may have interests or relationships that could affect their independence regarding those transactions.
In addition, the amendment supplements the company’s existing forum selection clause. The revised clause now covers claims brought by stockholders, whether acting on their own behalf or on behalf of the corporation, if those claims relate to the company’s business, the conduct of its affairs, or the rights or powers of the corporation or its stockholders, directors, or officers.
The company stated that the changes were approved by its board of directors on Monday. The full text of the amended bylaws was included as an exhibit to the SEC filing.
Serina Therapeutics is incorporated in Delaware and is based in Huntsville, Alabama. The information in this article is based on a press release statement contained in the company’s SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.